Advertisement


Hyun C. Chung, MD, on Pembrolizumab for Advanced Cervical Cancer: Update From KEYNOTE-158

SGO 2021 Virtual Annual Meeting on Womens Cancer

Advertisement

Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy and whose tumors express PD-L1.



Related Videos

Gynecologic Cancers

Alice P. Barr, MD, on Advanced Ovarian Cancer: Minimally Invasive vs Open Surgery After Chemotherapy

Alice P. Barr, MD, of the Carolinas Medical Center and Levine Cancer Institute, discusses results from a retrospective study, which showed that progression-free and overall survival appeared to be no different with open surgery and minimally invasive surgery for interval debulking after neoadjuvant chemotherapy in women with advanced epithelial ovarian cancer. Perioperative outcomes also seemed to be superior with minimally invasive surgery (ID #10209).

Gynecologic Cancers
Immunotherapy

Amir A. Jazaeri, MD, on Metastatic Cervical Cancer: The Role of Immunotherapy

Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) to treat patients with recurrent, metastatic, or persistent cervical carcinoma whose tumors have progressed on prior systemic therapy (ID # 10224).

Gynecologic Cancers

Laura Chambers, DO, on Treating Epithelial Ovarian Cancer With Cisplatin and Paclitaxel During Surgery

Laura Chambers, DO, of the Cleveland Clinic, discusses data showing that combining paclitaxel and cisplatin vs cisplatin alone with hyperthermic intraperitoneal chemotherapy at interval debulking surgery improved progression-free survival. There was no difference in postoperative complications, length of stay, or time to chemotherapy, but admission to intensive care units did increase.

Gynecologic Cancers
COVID-19

Brian M. Slomovitz, MD, on the Impact of COVID-19 on Gynecologic Cancer Research

Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patient accrual by 50% in 2020 (ID # 10215).

Gynecologic Cancers
Pain Management

Brittany A. Davidson, MD, on a Model to Predict the Need for Opioids After Gynecologic Surgery

Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-centered predictive tool designed to help avoid overprescribing pain medications (ID# 10253).

Advertisement

Advertisement




Advertisement